Skip to content

Nektar Therapeutics NKTR Accrued Manufacturing Costs

Accrued Manufacturing Costs at other companies

Incyte logo
IncyteINCY
Arcus Biosciences logo
Arcus BiosciencesRCUS
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
Johnson & Johnson logo
Johnson & JohnsonJNJ

Other financials

Income statement

See full
Revenue$10.9M+3.8%
Gross profit$21.8M+2.9%
Operating income-$39.1M+12.3%
Net income-$44.9M+11.7%
EPS (diluted)-$1.82+49.7%

Balance sheet

See full
Cash & equivalents$5.7M-20.0%
Total debt$83.2M-17.1%
Total equity$576.2M+4,094%
Total assets$763.3M+198%

Cash flow

See full
Operating cash flow-$44.3M+9.7%
CapEx$18.0K+800%
Free cash flow-$44.3M+9.7%

Valuation

See full
Market cap$2.19B+1,531%

Profitability

See full
Gross margin100%+31.2pp
Operating margin-242%
Net margin-284.2%+937pp
FCF margin-366.6%+1,421pp

Returns & leverage

See full
Return on equity-53.6%-22.6pp
Debt / equity0.1×-7.2×
Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.

The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nektar Therapeutics's accrued manufacturing costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nektar Therapeutics's accrued manufacturing costs?
Nektar Therapeutics (NKTR) reported accrued manufacturing costs of $5.01M in Q1 2026.
How has Nektar Therapeutics's accrued manufacturing costs changed year-over-year?
Nektar Therapeutics's accrued manufacturing costs decreased by 0.4% year-over-year, from $5.03M to $5.01M.
What is the long-term trend for Nektar Therapeutics's accrued manufacturing costs?
Over 5 years (2020 to 2025), Nektar Therapeutics's accrued manufacturing costs has grown at a -27.4% compound annual growth rate (CAGR), from $14.53M to $2.94M.